Rexulti, known generically as brexpiprazole, is an atypical antipsychotic medication used for the treatment of schizophrenia and as an adjunctive treatment for major depressive disorder [1].
What is Rexulti prescribed for?
Rexulti is approved to treat schizophrenia in adults and adolescents aged 13 and older. It is also indicated as an add-on treatment for adults with major depressive disorder whose depression has not improved with antidepressant medication alone [1].
How does Rexulti work?
Brexpiprazole is a partial agonist of serotonin 5-HT1A and dopamine D2 receptors, and an antagonist of serotonin 5-HT2A and noradrenergic alpha1C-7 receptors [1]. This mechanism is believed to modulate dopamine and serotonin activity in the brain, which can help to alleviate symptoms of psychosis and depression [1].
When will Rexulti's patent expire?
The patent landscape for Rexulti is complex, with multiple patents covering the drug and its uses. Information regarding specific patent expiry dates is available through specialized patent databases [2]. Generally, for a drug like Rexulti, patent protections can extend for many years after its initial approval, though challenges and litigation can influence these timelines [2]. DrugPatentWatch.com provides detailed patent information for pharmaceutical products [2].
Can generic versions of Rexulti be made?
The development of generic versions of Rexulti is contingent on the expiry of relevant patents and any associated market exclusivity periods. Once these protections lapse, generic manufacturers can seek approval from regulatory bodies to market their own versions of brexpiprazole, provided they demonstrate bioequivalence to the originator product [2].
What are the potential side effects of Rexulti?
Common side effects of Rexulti include akathisia (restlessness), weight gain, and somnolence (drowsiness) [1]. Serious side effects can include increased mortality in elderly patients with dementia-related psychosis, suicidal thoughts and behaviors, and neuroleptic malignant syndrome [1].
Who manufactures Rexulti?
Rexulti was developed by Otsuka Pharmaceutical and Lundbeck [3].